How it started
History
In 2010, Panaxia was founded as the cannabis division of the Segal Pharma Group, a group of private companies in the pharmaceutical and medical device spaces. Upon its establishment, the company began research and development in the field of medical cannabis.
In 2016, upon the government's announcement of the outline for medicalization of medical cannabis products, Panaxia Pharmaceutical Industries Ltd. was founded by Dr. Dadi Segal, Dr. Eran Goldberg and Adv. Assi Rotbart as a separate company controlled by the Segal Group.
In 2018, Panaxia began cooperating with Rafa Laboratories, which was the first pharmaceutical company in Israel to enter the medical cannabis arena. As part of this partnership, Panaxia manufacturers cannabis oils for Rafa under the Axiban brand. In 2018, Panaxia began distributing medical cannabis products to various pharmacies in Israel.
In November 2018, Panaxia was listed on the Tel Aviv Stock Exchange and signed a memorandum of understanding to merge its activity in Israel into the publicly traded company, Herodium Investments.
In June 2020, Panaxia announced that it had been granted EU GMP standard from an EU Health Authority, which is required for commercial production and export of medical cannabis and medical cannabis products to Europe. Panaxia is the first and only company in Israel to have been granted this. In July 2020, Panaxia signed a partnership agreement with the European pharmaceutical company, Neuraxpharm. Under the agreement, both companies will produce cannabis-based medicines and products for medical purposes and will market and distribute them in Germany.
From Wikipedia’s article on Panaxia, shared under CC BY-SA 4.0.2